Ambroxol is a high-potency inhibitor of voltage-gated sodium channels Nav1.7 and Nav1.8 responsible for nociceptive and neuropathic pain. This study investigated the analgesic property of ambroxol on corneal pain in rats as well as its toxicity on human corneal epithelial cells.
Methods:
Inhibition of corneal sensation (CS) by ambroxol hydrochloride (AH) in Sprague–Dawley rats was assessed by Cochet–Bonnet esthesiometer. Rat corneal pain was induced by administering 5 M NaCl drops to the eyes, and eye wiping rates were recorded to reflect pain intensity. Subsequently, a rat neuropathic corneal pain (NCP) model was created by first removing the corneal epithelium and then provoking pain with 2 M NaCl. The analgesic property of 0.5% AH eye drop was assessed in rats by reductions in eye wiping rates. In cultured human corneal epithelial cells, the adverse effects of AH on cell migration and viability were studied by cell scratch and Cell Counting Kit-8 tests.
Results:
It was noted that 0.5% AH could significantly inhibit CS, and 0.5% AH is efficacious in suppressing rat corneal pain as well as heightened nociceptor sensitivity from repetitive stimulation from irritants. At concentrations up to 30 μM, AH does not affect corneal epithelial cell migration, cell proliferation, and viability.
Conclusions:
Selective blockage of key nociceptors of the cornea by ambroxol is effective in suppressing corneal pain and heightened nociceptor excitability, leading to modulation of NCP. Sparing certain CS could translate into more protection to the ocular surface. No overt toxicity of ambroxol was seen in cultured human corneal epithelial cells in this study.
GuthoffRF, WienssH, HahnelC, et al.Epithelial innervation of human cornea: A three-dimensional study using confocal laser scanning fluorescence microscopy. Cornea, 2005; 24(5):608–613.
LiuC, LinMT, LeeIXY, et al.Neuropathic corneal pain: Tear proteomic and neuromediator profiles, imaging features, and clinical manifestations. Am J Ophthalmol, 2024; 265:6–20.
5.
AndersenHH, YosipovitchG, GalorA. Neuropathic symptoms of the ocular surface: Dryness, pain, and itch. Curr Opin Allergy Clin Immunol, 2017; 17(5):373–381.
6.
CostiganM, ScholzJ, WoolfCJ. Neuropathic pain: A maladaptive response of the nervous system to damage. Annu Rev Neurosci, 2009; 32:1–32.
7.
GoyalS, HamrahP. Understanding neuropathic corneal pain–gaps and current therapeutic approaches. Semin Ophthalmol, 2016; 31(1–2):59–70.
8.
IftincaM, DefayeM, AltierC. TRPV1-Targeted drugs in development for human pain conditions. Drugs, 2021; 81(1):7–27.
9.
HameedS. Na(v)1.7 and Na(v)1.8: Role in the pathophysiology of pain. Mol Pain, 2019; 15:1744806919858801.
10.
MaRSY, KayaniK, Whyte-OshodiD, et al.Voltage gated sodium channels as therapeutic targets for chronic pain. J Pain Res, 2019; 12:2709–2722.
11.
Dib-HajjSD, BinshtokAM, CumminsTR, et al.Voltage-gated sodium channels in pain states: Role in pathophysiology and targets for treatment. Brain Res Rev, 2009; 60(1):65–83.
12.
DelwigA, LiuG, MengID, et al.NaV1.7 inhibitors relieve ocular discomfort in a rat model of dry eye disease. Investigative Ophthalmology & Visual Science, 2020; 61(7):143.
13.
MecumNE, RussellR, LeeJ, et al.Optogenetic inhibition of Nav1.8 expressing corneal afferents reduces persistent dry eye pain. Invest Ophthalmol Vis Sci, 2021; 62(14):15.
14.
RussoMA, BaronR, DickensonAH, et al.Ambroxol for neuropathic pain: Hiding in plain sight? Pain, 2023; 164(1):3–13.
15.
RenovanzVK. Results of some clinical-pharmacological studies on ambroxol (NA 872). Arzneimittelforschung, 1975; 25(4):646–652.
16.
MalerbaM, RagnoliB. Ambroxol in the 21st century: Pharmacological and clinical update. Expert Opin Drug Metab Toxicol, 2008; 4(8):1119–1129.
17.
BeehKM, BeierJ, EsperesterA, et al.Antiinflammatory properties of ambroxol. Eur J Med Res, 2008; 13(12):557–562.
18.
GillissenA, NowakD. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med, 1998; 92(4):609–623.
19.
WeiserT. Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1.2 channels. Neurosci Lett, 2006; 395(3):179–184.
20.
WeiserT, WilsonN. Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol. Mol Pharmacol, 2002; 62(3):433–438.
21.
SchutzA, GundHJ, PschornU, et al.Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat. Clinical proof of concept. Arzneimittelforschung, 2002; 52(3):194–199.
22.
KernKU, Schwickert-NieswandtM, MaihofnerC, et al.Topical Ambroxol 20% for the treatment of classical trigeminal neuralgia - A new option? Initial clinical case observations. Headache, 2019; 59(3):418–429.
23.
KernKU, WeiserT. Topical ambroxol for the treatment of neuropathic pain. An initial clinical observation. Schmerz, 2015; 29(Suppl 3):S89–S96.
24.
YuL, BhattacharyaD, WangZ, et al.Topical administration of ambroxol eye drops augments tear secretion in rabbits. Graefes Arch Clin Exp Ophthalmol, 2021; 259(6):1529–1538.
25.
WangZ, YuL, ZhangS, et al.An animal study on the effect of topically administered ambroxol for dry eye. Front Biosci (Landmark Ed), 2022; 27(1):4.
26.
GolebiowskiB, PapasE, StapletonF. Assessing the sensory function of the ocular surface: Implications of use of a non-contact air jet aesthesiometer versus the Cochet-Bonnet aesthesiometer. Exp Eye Res, 2011; 92(5):408–413.
27.
FarazifardR, SafarpourF, SheibaniV, et al.Eye-wiping test: A sensitive animal model for acute trigeminal pain studies. Brain Res Brain Res Protoc, 2005; 16(1–3):44–49.
28.
LiangCC, ParkAY, GuanJL. In vitro scratch assay: A convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc, 2007; 2(2):329–333.
29.
ShapiroJN, AbuzaitounRO, PanY, et al.Health care use for eye pain. JAMA Ophthalmol, 2024; 142(7):655–660.
30.
YuJ, AscheCV, FairchildCJ. The economic burden of dry eye disease in the United States: A decision tree analysis. Cornea, 2011; 30(4):379–387.
31.
YagciA, BozkurtB, EgrilmezS, et al.Topical anesthetic abuse keratopathy: A commonly overlooked health care problem. Cornea, 2011; 30(5):571–575.
32.
GaynesBI, FiscellaR. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: A safety review. Drug Saf, 2002; 25(4):233–250.
33.
Burling-PhillipsL. Topical NSAIDs: Best practices for safe use. EyeNet, 2013.
34.
SrinivasanM, MascarenhasJ, RajaramanR, et al.; Steroids for Corneal Ulcers Trial Group. The steroids for corneal ulcers trial: Study design and baseline characteristics. Arch Ophthalmol, 2012; 130(2):151–157.
35.
BennettDL, ClarkAJ, HuangJ, et al.The role of voltage-gated sodium channels in pain signaling. Physiol Rev, 2019; 99(2):1079–1151.
36.
XiaoY, BarbosaC, PeiZ, et al.Increased resurgent sodium currents in Nav1.8 contribute to nociceptive sensory neuron hyperexcitability associated with peripheral neuropathies. J Neurosci, 2019; 39(8):1539–1550.
37.
BirdEV, ChristmasCR, LoescherAR, et al.Correlation of Nav1.8 and Nav1.9 sodium channel expression with neuropathic pain in human subjects with lingual nerve neuromas. Mol Pain, 2013; 9:52.
38.
FurgałaA, FijałkowskiŁ, NowaczykA, et al.Time-shifted co-administration of sub-analgesic doses of ambroxol and pregabalin attenuates oxaliplatin-induced cold allodynia in mice. Biomed Pharmacother, 2018; 106:930–940.
39.
JensenTS, BaronR, HaanpaaM, et al.A new definition of neuropathic pain. Pain, 2011; 152(10):2204–2205.
40.
RajaSN, RingkampM, GuanY, et al.John J. Bonica award lecture: Peripheral neuronal hyperexcitability: The “low-hanging” target for safe therapeutic strategies in neuropathic pain. Pain, 2020; 161(Suppl 1):S14–S26.
41.
CardosoFC, LewisRJ. Sodium channels and pain: From toxins to therapies. Br J Pharmacol, 2018; 175(12):2138–2157.
42.
Kocot-KępskaM, ZajączkowskaR, MikaJ, et al.Topical treatments and their molecular/cellular mechanisms in patients with peripheral neuropathic pain-narrative review. Pharmaceutics, 2021; 13(4):450.
43.
KopytovaAE, RychkovGN, NikolaevMA, et al.Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Parkinsonism Relat Disord, 2021; 84:112–121.
44.
BernatonieneJ, SciupokasA, KopustinskieneDM, et al.Novel drug targets and emerging pharmacotherapies in neuropathic pain. Pharmaceutics, 2023; 15(7):1799.
45.
MatsudaM, HuhY, JiRR. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J Anesth, 2019; 33(1):131–139.
46.
JiangX, ZhangJ, KouB, et al.Ambroxol improves neuronal survival and reduces white matter damage through suppressing endoplasmic reticulum stress in microglia after intracerebral hemorrhage. Biomed Res Int, 2020; 2020:7941716.
47.
KantarA, KlimekL, CazanD, et al.An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children. Multidiscip Respir Med, 2020; 15(1):511.
